-
公开(公告)号：EP3954382A1
公开(公告)日：2022-02-16
申请号：EP20784004.2
申请日：2020-04-03
发明人： BAN, Hitoshi , TAKANASHI, Yosuke , IMAZAKI, Yusuke
IPC分类号： A61K39/00 , A61P35/00 , A61P37/04 , A61P43/00 , C07D473/18 , C07K14/47 , A61K9/107 , A61K47/02 , A61K47/10 , A61K47/14 , A61K31/522
摘要： The present invention relates to a compound useful as a vaccine adjuvant for cancer vaccine, a preparation process thereof, a pharmaceutical composition comprising the compound, and use of the compound as a vaccine adjuvant for cancer vaccine.
-
公开(公告)号：EP3868741A1
公开(公告)日：2021-08-25
申请号：EP21164640.1
申请日：2016-10-06
IPC分类号： C07D239/49 , A61K39/00 , A61K39/39 , A61P37/04
摘要： The present invention provides a compound of the formula (1) :
wherein X, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , Y 1 , Y 2 , L, and m are as defined in the description, and a pharmaceutically acceptable salt thereof, which are useful as a vaccine adjuvant.-
公开(公告)号：EP2982681B1
公开(公告)日：2018-08-22
申请号：EP14775899.9
申请日：2014-03-28
发明人： LI, Chiang Jia , BAN, Hitoshi , NISHIO, Yukihiro , GOTO, Masashi , NISHIHARA, Toshio , TAKANASHI, Yosuke
CPC分类号： A61K39/0011 , A61K39/00 , A61K47/646 , A61K2039/55 , A61K2039/55511 , A61K2039/55566 , A61K2039/572 , A61K2039/64 , A61K2039/70 , C07K7/06 , C07K7/08 , C07K14/00 , C07K14/4748
摘要： The present invention provides a compound represented by the formula (1): wherein X a and Y a are each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7 - 30 amino acid residues, R 1 is a hydrogen atom, a group represented by the formula (2): wherein X b and Y b are each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7 - 30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7 - 30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.
-
公开(公告)号：EP3323809A1
公开(公告)日：2018-05-23
申请号：EP16814362.6
申请日：2016-06-21
IPC分类号： C07D233/88 , A61K31/4365 , A61K31/437 , A61K31/4375 , A61K31/4709 , A61K45/00 , A61P35/00 , A61P35/02 , A61P43/00 , C07D401/12 , C07D403/12 , C07D405/12 , C07D405/14 , C07D471/04 , C07D491/056 , C07D495/04 , C07D498/04 , C07D513/04
CPC分类号： C07D491/056 , A61K31/4365 , A61K31/437 , A61K31/4375 , A61K31/4709 , A61K45/00 , A61P35/02 , C07D233/88 , C07D401/12 , C07D403/12 , C07D405/12 , C07D405/14 , C07D471/04 , C07D495/04 , C07D498/04 , C07D513/04
摘要： The present invention provides a bicyclic heterocyclic amide derivative of formula (1) wherein ring Q 1 is optionally-substituted C 6-10 aryl group, etc.; R 1 and R 2 are independently hydrogen atom, etc.; W 1 is optionally-substituted C 1-4 alkylene group; W 2 is -NR 3a C(O)-, etc. wherein R 3a is hydrogen atom or C 1-6 alkyl group; Cy 1 is the following group of formula (11), etc.; ring Q 2 is optionally-substituted benzene ring, etc.; n and m are indepndently 0, 1 or 2, provided that n and m are not simultaneously 0; X is NR 5 , etc.; R 5 is hydrogen atom, etc.; p is 1, 2, 3, 4 or 5; R 4 is, independently when two or more exist, hydrogen atom, etc.; and a pharmacologically acceptable salt thereof, which have a potent inhibitory effect on the sphere-forming ability of cancer cells and are useful as an orally-available anti-tumor agent.
-
公开(公告)号：EP3845533A1
公开(公告)日：2021-07-07
申请号：EP19854536.0
申请日：2019-08-26
发明人： KAMIOKA, Seiji , BAN, Hitoshi , SHIMADA, Naoaki , HIROSE, Wataru , ARAKAWA, Akihiko , YAMAZAKI, Kazuto , HIRA, Kenjiro
IPC分类号： C07D471/10 , A61K31/506 , A61K45/00 , A61P35/00 , A61P35/02 , A61P43/00 , C07D487/10
摘要： The present invention relates to the compound of formula (1a) wherein p is 1 or 2, R 1 - R 4 are hydrogen atom or the like, and a - d are 1 or 2, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.
-
公开(公告)号：EP3686182A1
公开(公告)日：2020-07-29
申请号：EP18859459.2
申请日：2018-09-21
IPC分类号： C07C229/12 , A61K31/265 , A61K31/27 , A61K31/352 , A61K31/36 , A61K31/381 , A61K31/453 , A61P43/00 , C07C271/52 , C07C271/54 , C07D307/92 , C07D311/92 , C07D317/64 , C07D405/04 , C07D495/04
摘要： The present invention addresses the problem of providing a novel chemically activated water-soluble prodrug. The present invention provides a compound represented by formula (1), or a pharmacologically acceptable salt thereof (in the formula, A represents A-0; X 1 and X 2 are the same as or different from each other and each independently represent a hydroxyl group or -O-C(=O)-Y-(C(R 1A )(R 1B ))n-NH-R 2 , where X 1 and X 2 are not simultaneously hydroxyl groups, n is 2, 3, or 4, Y represents an oxygen atom or -NR 4 , R 1A and R 1B are the same as or different from each other and each independently represent a hydrogen atom, etc., and R 2 represents a hydrogen atom, etc.; and R a to R d are optionally present, are the same as or different from each other, and each independently represent a hydrogen atom, etc.).
-
公开(公告)号：EP3604325A1
公开(公告)日：2020-02-05
申请号：EP18775236.5
申请日：2018-03-29
发明人： BAN, Hitoshi , TAKANASHI, Yosuke
摘要： The present disclosure relates to a WT1 peptide having a cysteine residue and including 10 to 12 residues, a peptide conjugate containing the same, and a combination of the WT1 peptide or the peptide conjugate and a WT1 helper peptide.
-
8.发明公开
公开(公告)号：EP3549957A1
公开(公告)日：2019-10-09
申请号：EP17875568.2
申请日：2017-11-29
发明人： BAN, Hitoshi , GOTO, Masashi , TAKANASHI, Yosuke
摘要： The present application relates to WT1 helper peptides consisting of an amino acid sequence of 9 to 30 amino acid residues including a sequence: KLSHL as part thereof, and combinations of a WT1 helper peptide and a conjugate of cancer antigen peptides.
-
公开(公告)号：EP3949983A1
公开(公告)日：2022-02-09
申请号：EP20784003.4
申请日：2020-04-03
发明人： BAN, Hitoshi , TAKANASHI, Yosuke , GOTO, Masashi , SUGINOBE, Natsuko , IMAZAKI, Yusuke , IWATA, Yoshiko
IPC分类号： A61K39/00 , A61P37/04 , C07K14/47 , A61K9/107 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/26 , A61K47/34 , A61K47/44 , C07D239/49
摘要： The present invention relates to a compound useful as a vaccine adjuvant for cancer vaccine, a preparation process thereof, a pharmaceutical composition comprising the compound, and use of the compound as a vaccine adjuvant for cancer vaccine.
-
公开(公告)号：EP3355933B1
公开(公告)日：2020-05-06
申请号：EP16782095.0
申请日：2016-09-28
发明人： BAN, Hitoshi , NISHIO, Yukihiro , MALYALA, Padma , MURALIDHARA, Bilikallahalli K. , WONG, Marcus
IPC分类号： A61K47/54 , A61K47/69 , A61P35/00 , A61K31/522 , C07D473/34
-
-
-
-
-
-
-
-
-
搜索结果
18 条记录 (耗时 0.021 秒)
